Good manufacturing practice production of adenoviral vectors for clinical trials

Human Gene Therapy

Volumn 16, Issue 3, 2005, Pages 281-291

  Lusky, Monika ^a  

^a TRANSGENE S A   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ONCOLYTIC VIRUS; VACCINE;

CANCER THERAPY; COMPLEMENT SYSTEM; DRUG DESIGN; DRUG PURIFICATION; GENE THERAPY; HUMAN; NONHUMAN; PRACTICE GUIDELINE; PROPHYLAXIS; QUALITY CONTROL; REVIEW; VIRUS RECOMBINANT;

ADENOVIRIDAE; GENE THERAPY; GENETIC VECTORS; QUALITY CONTROL; TECHNOLOGY, PHARMACEUTICAL; VIRAL VACCINES; VIRUS CULTIVATION;

EID: 16344377051     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2005.16.281     Document Type: Review

References (56)

1. ANONYMOUS (2004a). Manufacturing Gendicine: An exclusive talk with SiBiono's CEO about the first gene therapy. Biopharm. Int. 17, 42-49.
2. ANONYMOUS (2004b). Monograph 2322: Vectori adenoviri ad usum humanum. Pharmeuropa Bio. 16, 611-614.
3. ARCAND, N., BERNIER, A., TRANSFIGURACION, J., JACOB, D., COELHO, H., and KAMEN, A. (2003). Adenovirus type 5 (Ad5) chromatographic purification process at 20L scale. Bioprocess J. 2, 72-75.
4. BAROUCH, D.H., and NABEL, G.J. (2005). Adenovirus vector-based vaccines for human immunodeficiency virus type 1. Hum. Gene Ther. 16, 149-156.
5. BOYER, J.L., KOBINGER, G., WILSON, J.M., and CRYSTAL, R.G. (2005). Adenovirus-based genetic vaccines for biodefense. Hum. Gene Ther. 16, 157-168.
6. CHARTIER, C., DEGRYSE, E., GANTZER, M., DIETERLE, A., PAVIRANI, A., and MEHTALI, M. (1996). Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli. J. Virol. 70, 4805-4810.
7. CORTIN, V., THIBAULT, J., JACOB, D., and GARNIER, A. (2004). High-titer adenovirus vector production in 293S cell perfusion culture. Biotechnol. Prog. 20, 858-863.
8. COTE, J., BOURGET, L., GARNIER, A., and KAMEN, A. (1997). Study of adenovirus production in serum-free 293SF suspension culture by GFP-expression monitoring. Biotechnol. Prog. 13, 709-714.
9. DOERFLER, W., and BOEHM, P. (eds.). (2003a). Adenoviruses: Model and Vectors in Virus-Host Interactions. Immune System, Oncogenesis, Gene Therapy. Curr. Top. Microbiol. Immunol. 273.
10. DOERFLER, W., and BOEHM, P. (eds.). (2003b). Adenoviruses: Model and Vectors in Virus-Host Interactions. Virion and Structure, Viral Replication, Host Cell Interactions. Curr. Top. Microbiol. Immunol. 272.
11. EUDRALEX (2004). Medicinal Products for Human and Veterinary Use: Good Manufacturing Practice [last update August 30, 2004]. Available at URL http://pharmacos.eudra.org/F2/eudralex/vol-4/home.htm (accessed February 2005).
12. EUROPEAN AGENCY FOR THE EVALUATION OF MEDICINAL PRODUCTS (EMEA) (2003). Concept Paper on Development of Good Manufacturing Practices Guidance for Gene Therapy and Somatic Cell Therapy Medicinal Products. EMEA/INS/GMP/3379/03. Available at URL http://www.emea.eu.int/Inspections/docs/337903en.pdf (accessed February 2005).
13. EVANS, R.K., NAWROCKI, D.K., ISOPI, L.A., WILLIAMS, D.M., CASIMIRO, D.R., CHIN, S., CHEN, M., ZHU, D.M., SHIVER, J.W., and VOLKIN, D.B. (2004). Development of stable liquid formulations for adenovirus-based vaccines. J. Pharm. Sci. 93, 2458-2475.
14. FALLAUX, F.J., BOUT, A., VAN DER VELDE, I., VAN DEN WOLLENBERG, D.J., HEHIR, K.M., KEEGAN, J., AUGER, C., CRAMER, S.J., VAN ORMONDT, H., VAN DER EB, A.J., VALERIO, D., and HOEBEN, R.C. (1998). New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Hum. Gene Ther. 9, 1909-1917.
15. FOOD AND DRUG ADMINISTRATION, CENTER FOR BIOLOGICS EVALUATION AND REVIEW (FDA/CBER) (2004). Guidance for Industry: Drug Substance, Chemistry, Manufacturing, and Controls Information [draft]. Available at URL http://www.fda.gov/cber/gdlns/drugsubcmc.pdf (accessed February 2005).
16. GARNIER, A., COTE, J., NADEAU, I., KAMEN, A., and MASSIE, B. (1994). Scale-up of the adenovirus expression system for the production of recombinant protein in human 293S cells. Cytotechnology 15, 145-155.
17. GILBERT, P.A., GARNIER, A., JACOB, D., and KAMEN, A. (2000). On-line measurement of green fluorescent protein (GFP) fluorescence for the monitoring of recombinant adenovirus production. Biotechnol. Lett. 22, 561-567.
18. GLOECKLER, R. (2004). Manufacturing gene transfer vectors: From lab to market. Presented at the Biophex conference Post-Discovery through Commercialization, September 28-30, 2004, San Francisco, CA.
19. GRAHAM, F.L., SMILEY, J., RUSSELL, W.C., and NAIRN, R. (1977). Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 36, 59-74.
20. HEHIR, K.M., ARMENTANO, D., CARDOZA, L.M., CHOQUETTE, T.L., BERTHELETTE, P.B., WHITE, G.A., COUTURE, L.A., EVERTON, M.B., KEEGAN, J., MARTIN, J.M., PRATT, D.A., SMITH, M.P., SMITH, A.E., and WADSWORTH, S.C. (1996). Molecular characterization of replication-competent variants of adenovirus vectors and genome modifications to prevent their occurrence. J. Virol. 70, 8459-8467.
21. HERMENS, W.T., and VERHAAGEN, J. (1998). Suppression of inflammation by dexamethasone prolongs adenoviral vector-mediated transgene expression in the facial nucleus of the rat. Brain Res. Bull. 47, 133-140.
22. HUTCHINS, B. (2000). Development of a Reference Material for Characterizing Adenovirus Vectors. Available at URL http://www.wilbio.com/ ReferenceMaterials/pdfs/RelatedArticles001.pdf (accessed February 2005).
23. HUTCHINS, B., SAJJADI, N., SEAVER, S., SHEPHERD, A., BAUER, S.R., SIMEK, S., CARSON, K., and AGUILAR-CORDOVA, E. (2000). Working toward an adenoviral vector testing standard. Mol. Ther. 2, 532-534.
24. HUYGHE, B.G., LIU, X., SUTJIPTO, S., SUGARMAN, B.J., HORN, M.T., SHEPARD, H.M., SCANDELLA, C.J., and SHABRAM, P. (1995). Purification of a type 5 recombinant adenovirus encoding human p53 by column chromatography. Hum. Gene Ther. 6, 1403-1416.
25. IMLER, J.L., BOUT, A., DREYER, D., DIETERLE, A., SCHULTZ, H., VALERIO, D., MEHTALI, M., and PAVIRANI, A. (1995). Trans-complementation of El-deleted adenovirus: A new vector to reduce the possibility of codissemination of wild-type and recombinant adenoviruses. Hum. Gene Ther. 6, 711-721.
26. INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE (ICH) STEERING COMMITTEE (1998). ICH-Q5A: Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin. Available at URL http://www.ich.org/ MediaServer.jser?@_ID=425&@_MODE=GLB (accessed February 2005).
27. IRISH, T., BAKKER, W., FRIESNER, B., ABRAHAM, G., TUIJN, C., LARDENOIJE, R., and ETCHBERGER, K. (2000). A Comparative Study of Large-Scale Production Strategies Used to Produce RCA Free Adenovirus Preparations in Serum-Free Media. Available at URL http://www.jrhbio.com/pdf/r010.pdf (accessed February 2005).
28. IYER, P., OSTROVE, J.M., and VACANTE, D. (1999). Comparison of manufacturing techniques for adenovirus production. Cytotechnology 30, 169-172.
29. JOHNSON, L., SHEN, A., BOYLE, L., KUNICH, J., PANDEY, K., LEMMON, M., HERMISTON, T., GIEDLIN, M., MCCORMICK, F., and FATTAEY, A. (2002). Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agents. Cancer Cell 1, 325-337.
30. JONES, S.D., and LEVINE, H.L. (2004). Impact of the EU Clinical Trials Directive and other recent regulatory changes on the manufacture of biopharmaceuticals. Preclinica 2, 301-304.
31. KAMEN, A., and HENRY, O. (2004). Development and optimization of an adenovirus production process. J. Gene Med. 6(Suppl. 1), S184-S192.
32. KIRN, D. (2002). Replication-selective oncolytic adenovirus E1-region mutants: Virotherapy for cancer. In Adenoviral Vectors for Gene Therapy. D.T. Curiel and J.T. Douglas, eds. (Academic Press, San Diego, CA) pp. 329-374.
33. KLYUSHNICHENKO, V., BERNIER, A., KAMEN, A., and HARMSEN, E. (2001). Improved high-performance liquid chromatographic method in the analysis of adenovirus particles. J. Chromatogr. B Biomed. Sci. Appl. 755, 27-36.
34. LIU, M., ACRES, B., BALLOUL, J.M., BIZOUARNE, N., PAUL, S., SLOS, P., and SQUIBAN, P. (2004). Gene-based vaccines and immunotherapeutics. Proc. Natl. Acad. Sci. U.S.A. 101, 14567-14571.
35. LOCHMÜLLER, H., JANI, A., HUARD, J., PRESCOTT, S., SIMONEAU, M., MASSIE, B., KARPATI, G., and ACSADI, G. (1994). Emergence of early region 1-containing replication-competent adenovirus in stocks of replication-defective adenovirus recombinants (ΔE1 + ΔE3) during multiple passages in 293 cells. Hum. Gene Ther. 5, 1485-1491.
36. LOUIS, N., EVELEGH, C., and GRAHAM, F.L. (1997). Cloning and sequencing of the cellular-viral junctions from the human adenovirus type 5 transformed 293 cell line. Virology 233, 423-429.
37. LUSKY, M., CHRIST, M., RITTNER, K., DIETERLE, A., DREYER, D., MOUROT, B., SCHULTZ, H., STOECKEL, F., PAVIRANI, A., and MEHTALI, M. (1998). In vitro and in vivo biology of recombinant adenovirus vectors with E1, E1/E2A, or E1/E4 deleted. J. Virol. 72, 2022-2032.
38. LUSKY, M., DEGRYSE, E., MEHTALI, M., and CHARTIER, C. (2002). Adenoviral vector construction. II. Bacterial systems. In Adenoviral Vectors for Gene Therapy. D.T. Curiel and J.T. Douglas, eds. (Academic Press, San Diego, CA) pp. 105-127.
39. MAIZEL, J.V., WHITE, D.O., and SCHARFF, M.D. (1968). The polypeptides of adenovirus. I. Evidence for multiple protein components in the virion and a comparison of types 2, 7A, and 12. Virology 36, 115-125.
40. MCCONNELL, M.J., and IMPERIALE, M.J. (2004). Biology of adenovirus and its use as a vector for gene therapy. Hum. Gene Ther. 15, 1022-1033.
41. MITTEREDER, N., MARCH, K.L., and TRAPNELL, B.C. (1996). Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J. Virol. 70, 7498-7509.
42. MURAKAMI, P., PUNGOR, E., FILES, J., DO, L., VAN RIJNSOEVER, R., VOGELS, R., BOUT, A., and MCCAMAN, M. (2002). A single short stretch of homology between adenoviral vector and packaging cell line can give rise to cytopathic effect-inducing, helper-dependent E1-positive particles. Hum. Gene Ther. 13, 909-920.
43. NADEAU, I., and KAMEN, A. (2003). Production of adenovirus vector for gene therapy. Biotechnol. Adv. 20, 475-489.
44. NADEAU, I., GILBERT, P.A., JACOB, D., PERRIER, M., and KAMEN, A. (2002). Low-protein medium affects the 293SF central metabolism during growth and infection with adenovirus. Biotechnol. Bioeng. 77, 91-104.
45. NICHOLS, W.W., LARDENOIJE, R., LEDWITH, B.J., BROUWER, K., MANAM, S., VOGELS, R., KASLOW, D., ZUIDGEEST, D., BETT, A.J., CHEN, L., VAN DER KAADEN, M., GALLOWAY, S.M., HILL, R.B., MACHOTKA, S.V., ANDERSON, C.A., LEWIS, J., MARTINEZ, D., LEBRON, J., RUSSO, C., VALERIO, D., and BOUT, A. (2002). Propagation of adenoviral vectors: Use of PER.C6 cells. In Adenoviral Vectors for Gene Therapy. D.T. Curiel and J.T. Douglas, eds. (Academic Press, San Diego, CA) pp. 129-166.
46. NYBERG-HOFFMAN, C., SHABRAM, P., LI, W., GIROUX, D., and AGUILAR-CORDOVA, E. (1997). Sensitivity and reproducibility in adenoviral infectious titer determination. Nat. Med. 3, 808-811.
47. ROITSCH, C., ACHSTETTER, T., BENCHAIBI, M., BONFILS, E., CAUET, G., GLOECKLER, R., L'HOTE, H., KEPPI, E., NGUYEN, M., SPEHNER, D., VAN DORSSELAER, A., and MALARME, D. (2001). Characterization and quality control of recombinant adenovirus vectors for gene therapy. J. Chromatogr. B Biomed. Sci. Appl. 752, 263-280.
48. SEITZ, H., BLUEMEL, J., SCHMIDT, I., WILLKOMMEN, H., and LOEWER, J. (2002). Comparable virus inactivation by bovine or vegetable derived Tween 80 during solvent/detergent treatment. Biologicals 30, 197-205.
49. SHABRAM, P.W., GIROUX, D.D., GOUDREAU, A.M., GREGORY, R.J., HORN, M.T., HUYGHE, B.G., LIU, X., NUNNALLY, M.H., SUGARMAN, B.J., and SUTJIPTO, S. (1997). Analytical anion-exchange HPLC of recombinant type-5 adenoviral particles. Hum. Gene Ther. 8, 453-465.
50. SHABRAM, P.W., VELLEKAMP, G., and SCANDELLA, C. (2002). Purification of adenovirus. In Adenoviral Vectors for Gene Therapy. D.T. Curiel and J.T. Douglas, eds. (Academic Press, San Diego, CA) pp. 167-203.
51. SHENK, T. (1996). Adenoviridae: The viruses and their replication. In Fields Virology. B.N. Fields, D.M. Knipe, and P.M. Howley, eds. (Lippincott-Raven, New York) pp. 979-1016.
52. TRANSFIGURACION, J., BERNIER, A., ARCAND, N., CHAHAL, P., and KAMEN, A. (2001). Validation of a high-performance liquid chromatographic assay for the quantification of adenovirus type 5 particles. J. Chromatogr. B Biomed. Sci. Appl. 761, 187-194.
53. XIE, L., PILBROUGH, W., METALLO, C., ZHONG, T., PIKUS, L., LEUNG, J., AUNINS, J.G., and ZHOU, W. (2002). Serum-free suspension cultivation of PER.C6® cells and recombinant adenovirus production under different pH conditions. Biotechnol. Bioeng. 80, 569-579.
54. XIE, L., METALLO, C., WARREN, J., PILBROUGH, W., PELTIER, J., ZHONG, T., PIKUS, L., YANCY, A., LEUNG, J., AUNINS, J.G., and ZHOU, W. (2003). Large-scale propagation of a replication-defective adenovirus vector in stirred-tank bioreactor PER.C6 cell culture under sparging conditions. Biotechnol. Bioeng. 83, 45-52.
55. YUK, I.H., OLSEN, M.M., GEYER, S., and FORESTELL, S.P. (2004). Perfusion cultures of human tumor cells: A scalable production platform for oncolytic adenoviral vectors. Biotechnol. Bioeng. 86, 637-642.
56. ZHANG, S., PHAM, H., SENESAC, J., and GALLAGHER, S. (2003). Production of adenoviral vectors for gene therapy in suspension serum free cultures. Available at URL http://www.wavebiotech.com/pdfs/literature/ viralvectors02intgen.pdf (accessed February 2005).